Bortezomib-based Anthracycline-free Induction for Pediatric Relapsed ALL as a Bridge to Immunotherapy
Conclusion:
Anthracyclines can be safely omitted from bortezomib-based therapies in patients with R/R ALL, when planning to proceed to immunotherapy.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Article Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Children | Hematology | Immunotherapy | Leukemia | Pediatrics | Stem Cell Therapy | Stem Cells | Toxicology | Transplants | Velcade